Evidence map›Paper›PMID 35269532›Full record

ArticleCells2022

EZH2 and Endometrial Cancer Development: Insights from a Mouse Model.

Xin Fang, Nan Ni, Xiaofang Wang, Yanan Tian, Ivan Ivanov, Monique Rijnkels, Kayla J Bayless, John P Lydon, Qinglei Li

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cells, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.7field-weighted citation impact, top 34% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Role of EZH2 in Uterine Gland Development.International journal of molecular sciences · 2022
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Xin FangDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Nan NiDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Xiaofang WangDepartment of Biomedical Sciences, Texas A&M University College of Dentistry, Dallas, TX 75246, USA.
Yanan TianDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
Ivan IvanovDepartment of Veterinary Physiology and Pharmacology, Texas A&M University, College Station, TX 77843, USA.
Monique RijnkelsDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Kayla J BaylessDepartment of Molecular and Cellular Medicine, Texas A&M University Health Science Center, Bryan, TX 77807, USA.
John P LydonDepartment of Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Qinglei LiDepartment of Veterinary Integrative Biosciences, Texas A&M University, College Station, TX 77843, USA.
Texas A&M University · USBaylor College of Medicine · US

Funding

REPRODUCTIVE HORMONES: BIOLOGICAL AND MOLECULAR ACTIONSR01HD008188 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI DAVID M LONARD, JOHN P LYDON · 1985 to 2026
$16.3M
SEX HORMONE RECEPTOR COMPONENTS AND THE CELL GENOMER01HD007857 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI DAVID M LONARD, JOHN P LYDON · 1985 to 2026
$14.6M
Texas A&M Center for Environmental Health Research (TiCER)P30ES029067 · NIEHS · TEXAS A&M UNIVERSITY · PI Sakhila Banu · 2019 to 2026
$13.0M
Molecular Analysis of Uterine ReceptivityR01HD042311 · NICHD · BAYLOR COLLEGE OF MEDICINE · PI LYDON, JOHN P · 2009 to 2023
$4.8M
CRR LIGAND ASSAY AND ANALYSIS CORER24HD102061 · NICHD · UNIVERSITY OF VIRGINIA · PI HAISENLEDER, DANIEL J. · 2019 to 2023
$2.2M
TGF-BETA SIGNALING IN ENDOMETRIAL CELL FUNCTION AND DYSFUNCTIONR01HD087236 · NICHD · TEXAS A&M AGRILIFE RESEARCH · PI LI, QINGLEI · 2017 to 2021
$1.5M
Long noncoding RNA MALAT1 ablation reverses sepsis in mouse: epitranscriptomic mechanisms and therapeutic applicationR21AI152050 · NIAID · TEXAS A&M AGRILIFE RESEARCH · PI TIAN, YANAN · 2020 to 2021
$421k
NIAID NIH HHS R21 AI152050NICHD NIH HHS R01 HD007857NICHD NIH HHS R01 HD008188NICHD NIH HHS R01 HD042311NICHD NIH HHS R01 HD087236NICHD NIH HHS R24 HD102061NIEHS NIH HHS P30 ES029067
6 · The paper itself

Abstract

Enhancer of zeste homolog 2 (EZH2), a core component of polycomb repressive complex 2, plays an important role in cancer development. As both oncogenic and tumor suppressive functions of EZH2 have been documented in the literature, the objective of this study is to determine the impact of

Indexed as

Endometrial NeoplasmsEnhancer of Zeste Homolog 2 ProteinAnimalsCarcinogenesisDisease Models, AnimalFemaleHumansMicePolycomb Repressive Complex 2UterusEnhancer of Zeste Homolog 2 ProteinEZH2 protein, humanPolycomb Repressive Complex 2endometrial cancerEzh2mouse modelPten

Identifiers

PMID35269532
PMCPMC8909840
OpenAlexW4220725932

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.